Comprehensive molecular profiling of 5,175 esophagogastric cancer (EGC) patients identified distinct molecular signatures for early-onset (< 50 years of age, EOEGC, n=530) versus average-onset (AOEGC, n=4,645) tumors.
EOEGC has increased frequency of CDH1 mutations, ARHGAP26 fusions, enrichment of epithelial mesenchymal transition (EMT) and angiogenesis pathways, decreased MAPK pathway activity, decreased frequency of TMB-high and dMMR/MSI-H, and a unique immune cell infiltrate with decreased M1 macrophages and increased M2 macrophages.
These unique differential characteristics present therapeutic opportunities but also demonstrate the limitations of currently approved therapies in this subset of patients.
Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay
Abstract The precision oncology industry has evolved rapidly within the past two decades, although treatment selection remains a complex undertaking. Access to timely, accurate, and… […]
Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
Abstract Background Trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) increasingly used in HER2-negative breast cancer. We hypothesized that treatment benefit would… […]
